Scholar Rock (SRRK) Expected to Announce Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter.

Scholar Rock Trading Up 3.0 %

Shares of Scholar Rock stock opened at $39.15 on Friday. The stock has a market cap of $3.67 billion, a P/E ratio of -16.66 and a beta of 0.50. The stock’s 50 day simple moving average is $41.89 and its 200-day simple moving average is $28.17. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Insider Transactions at Scholar Rock

In related news, CEO Jay T. Backstrom sold 22,308 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $986,013.60. Following the sale, the chief executive officer now owns 330,363 shares in the company, valued at approximately $14,602,044.60. This trade represents a 6.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of Scholar Rock stock in a transaction on Monday, November 25th. The shares were sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the transaction, the insider now owns 10,850,005 shares in the company, valued at approximately $417,616,692.45. This trade represents a 3.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 559,407 shares of company stock valued at $21,686,786 in the last ninety days. Corporate insiders own 19.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. HC Wainwright boosted their target price on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Truist Financial boosted their target price on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Finally, Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a research report on Wednesday, January 29th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.